Published in Mol Biol Cell on June 01, 1997
Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol (1998) 1.13
Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell (2003) 0.88
Expression characterization and the promoter activity analysis of zebrafish hdac4. Fish Physiol Biochem (2011) 0.77
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain. Genes Dev (1988) 8.11
Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res (1985) 7.67
Basement membrane complexes with biological activity. Biochemistry (1986) 6.79
Regulation of differentiation of vascular smooth muscle cells. Physiol Rev (1995) 6.60
Purification and characterization of OTF-1, a transcription factor regulating cell cycle expression of a human histone H2b gene. Cell (1987) 5.04
Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science (1991) 4.27
Regulation of development and differentiation by the extracellular matrix. Development (1993) 4.13
Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol (1986) 3.77
Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc Natl Acad Sci U S A (1980) 3.57
The intima. Soil for atherosclerosis and restenosis. Circ Res (1995) 3.48
Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol (1981) 3.41
Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature (1977) 3.25
POU-domain transcription factors: pou-er-ful developmental regulators. Genes Dev (1991) 3.16
Multi-faceted regulation of cell differentiation by extracellular matrix. FASEB J (1993) 3.14
Laminin mediates tissue-specific gene expression in mammary epithelia. J Cell Biol (1995) 2.83
Octamania: the POU factors in murine development. Trends Genet (1991) 2.55
Cell-cycle regulation of a human histone H2b gene is mediated by the H2b subtype-specific consensus element. Genes Dev (1988) 2.47
Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem (1991) 2.47
Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res (1994) 2.46
Phenotype-dependent response of cultured aortic smooth muscle to serum mitogens. J Cell Biol (1981) 2.33
Structure and expression of the murine retinoblastoma gene and characterization of its encoded protein. Proc Natl Acad Sci U S A (1989) 2.25
The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem (1991) 2.23
A novel transcriptional enhancer is involved in the prolactin- and extracellular matrix-dependent regulation of beta-casein gene expression. Mol Biol Cell (1992) 2.15
Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J Cell Biol (1985) 2.05
Regulation of transcription and cell identity by POU domain proteins. Cell (1991) 1.94
The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J (1994) 1.87
An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol (1985) 1.83
Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells. J Cell Biol (1988) 1.73
Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest (1990) 1.73
Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol (1984) 1.71
Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry (1984) 1.70
Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. Am J Respir Cell Mol Biol (1990) 1.60
Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury. Circ Res (1992) 1.59
Smooth muscle phenotypic expression in human carotid arteries. I. Comparison of cells from diffuse intimal thickenings adjacent to atheromatous plaques with those of the media. Lab Invest (1985) 1.50
Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int Rev Cytol (1996) 1.46
Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol (1992) 1.37
Multiple phenotypically distinct smooth muscle cell populations exist in the adult and developing bovine pulmonary arterial media in vivo. Circ Res (1994) 1.37
Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem (1994) 1.29
Developmental changes in expression of contractile and cytoskeletal proteins in human aortic smooth muscle. J Biol Chem (1990) 1.23
Fibronectin and the basement membrane components laminin and collagen type IV influence the phenotypic properties of subcultured rat aortic smooth muscle cells differently. Cell Tissue Res (1994) 1.17
Differential expression of small chondroitin/dermatan sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem (1991) 1.17
Flow affects development of intimal hyperplasia after arterial injury in rats. Arterioscler Thromb (1992) 1.16
Heparin and related glycosaminoglycans modulate the secretory phenotype of vascular smooth muscle cells. J Cell Biol (1984) 1.11
Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein. Nucleic Acids Res (1988) 1.09
Developmental expression of the syndecans: possible function and regulation. Dev Suppl (1993) 1.08
Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol (1990) 1.07
Developmentally timed expression of an embryonic growth phenotype in vascular smooth muscle cells. Circ Res (1994) 1.05
An improved nuclear extract preparation method. Gene Anal Tech (1989) 1.03
Heterogeneous distribution of a basement membrane heparan sulfate proteoglycan in rat tissues. J Cell Biol (1987) 1.01
Relation between activated smooth-muscle cells in coronary-artery lesions and restenosis after atherectomy. N Engl J Med (1993) 0.97
Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J Biol Chem (1993) 0.94
Perlecan, the large low-density proteoglycan of basement membranes: structure and variant forms. Kidney Int (1993) 0.91
Regulated expression of syndecan in vascular smooth muscle cells and cloning of rat syndecan core protein cDNA. J Biol Chem (1992) 0.91
Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells. J Biol Chem (1992) 0.91
Recombinant domain III of perlecan promotes cell attachment through its RGDS sequence. J Biol Chem (1995) 0.87
Vascular smooth muscle cells grown on Matrigel. A model of the contractile phenotype with decreased activation of mitogen-activated protein kinase. J Biol Chem (1994) 0.85
Heparan sulfate-degrading enzymes induce modulation of smooth muscle phenotype. Exp Cell Res (1992) 0.84
Static tension is associated with increased smooth muscle cell DNA synthesis in rat pulmonary arteries. Am J Physiol (1995) 0.83
Developmental regulation of perlecan gene expression in aortic smooth muscle cells. Matrix Biol (1996) 0.81
Do cultured vascular smooth muscle cells resemble those of the artery wall? If not, why not? J Cardiovasc Pharmacol (1989) 0.80
Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis (1993) 0.80
Down regulation of the octamer binding protein Oct-1 during growth arrest and differentiation of a neuronal cell line. Brain Res Mol Brain Res (1995) 0.78
The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health (1995) 2.43
Role of basic fibroblast growth factor in vascular lesion formation. Circ Res (1991) 2.38
Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene (2008) 2.31
Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev (2001) 2.12
A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A (1990) 2.11
Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. Proc Natl Acad Sci U S A (1986) 2.10
Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J Cell Biol (1985) 2.05
Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol (1999) 1.91
An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol (1981) 1.80
Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest (1990) 1.73
Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol (1984) 1.71
Postsplenectomy sepsis and mortality in adults. JAMA (1982) 1.70
Small bowel motility in diabetics. Am J Dig Dis (1969) 1.64
Psychosocial benefits of a cancer support group. Cancer (1986) 1.62
Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to platelet-derived growth factor. J Biol Chem (1987) 1.62
Advanced squamous cell carcinoma of the cervix with recent normal Papanicolaou tests. Lancet (1980) 1.61
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med (1987) 1.60
A case-control study of cancer of the endometrium. Am J Epidemiol (1982) 1.50
Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures. J Cell Biol (1987) 1.48
Adenocarcinoma in situ of the cervix: management and outcome. Gynecol Oncol (1999) 1.45
Novel embryonic genes are preferentially expressed by autonomously replicating rat embryonic and neointimal smooth muscle cells. Circ Res (2000) 1.45
Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol (1993) 1.33
Quantitative export of FGF-2 occurs through an alternative, energy-dependent, non-ER/Golgi pathway. J Cell Physiol (1995) 1.30
Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol (1992) 1.25
Treatment of ovarian stromal tumors. Am J Obstet Gynecol (1976) 1.22
Distribution of estrogen receptor-beta-like immunoreactivity in rat forebrain. Neuroendocrinology (1997) 1.21
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer (2009) 1.20
Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev (1999) 1.19
Vascular smooth muscle cells express distinct transforming growth factor-beta receptor phenotypes as a function of cell density in culture. J Biol Chem (1989) 1.15
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene (2011) 1.12
Allelic loss in ovarian cancer. Int J Cancer (1993) 1.12
Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer (1987) 1.11
Heparin and related glycosaminoglycans modulate the secretory phenotype of vascular smooth muscle cells. J Cell Biol (1984) 1.11
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene (2012) 1.10
Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control (2001) 1.10
Heparin regulates the collagen phenotype of vascular smooth muscle cells: induced synthesis of an Mr 60,000 collagen. J Cell Biol (1985) 1.08
Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers. Cancer Res (1988) 1.08
Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys (1983) 1.06
Developmentally timed expression of an embryonic growth phenotype in vascular smooth muscle cells. Circ Res (1994) 1.05
Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int J Radiat Oncol Biol Phys (1989) 1.04
Urinary gonadotropin fragment, a new tumor marker. I. Assay development and cancer specificity. Gynecol Oncol (1990) 1.03
Pelvic masses in pregnancy: MR imaging. Radiology (1990) 1.02
The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene (2010) 1.02
Uterine papillary serous carcinoma. Obstet Gynecol (1987) 1.01
Structural organization of the Amy locus in seven strains of Drosophila melanogaster. Nucleic Acids Res (1986) 1.01
Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am J Clin Pathol (1990) 1.00
Stage IIIA carcinoma of the uterine cervix. Gynecol Oncol (1986) 1.00
High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. Int J Radiat Oncol Biol Phys (1988) 1.00
Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol (1990) 0.99
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer (2013) 0.99
Rapidly progressive squamous cell carcinoma of the cervix coexisting with human immunodeficiency virus infection: clinical opinion. Gynecol Oncol (1991) 0.99
Epithelial carcinoma of the ovary: current strategies. Ann Intern Med (1981) 0.98
Obstetric and nonmalignant gynecologic bleeding: treatment with angiographic embolization. Radiology (1987) 0.98
High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol (1993) 0.97
Carcinosarcoma of the ovary. Int J Gynecol Cancer (2007) 0.96
Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol (1988) 0.96
Steroid-receptor proteins in nonepithelial malignancies of the ovary. Gynecol Oncol (1983) 0.95
Radiation treatment of FIGO stage IVA carcinoma of the cervix. Gynecol Oncol (1989) 0.94
Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer (1992) 0.94
Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer (1991) 0.94
Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass. Gynecol Oncol (1990) 0.94
Multiple growth factors are released from mechanically injured vascular smooth muscle cells. Am J Physiol (1995) 0.94
Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol (1982) 0.93
Second-look operations in ovarian cancer. Am J Obstet Gynecol (1980) 0.93
Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol (1993) 0.93
Extramammary Paget's disease of the vulva. Gynecol Oncol (1995) 0.91
Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol Oncol (1987) 0.91
Structural organization of the alpha-amylase gene locus in Drosophila melanogaster and Drosophila miranda. Isozymes Curr Top Biol Med Res (1987) 0.91
Allele loss at the retinoblastoma locus in human ovarian cancer. J Natl Cancer Inst (1991) 0.90
Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol (2000) 0.90
Psychosocial reactions to the diagnosis of gynecologic cancer. Obstet Gynecol (1983) 0.89
Control of arterial hemorrhage using percutaneous arterial catheter techniques in patients with gynecologic malignancies. Gynecol Oncol (1975) 0.89
Fallopian tube carcinoma. Int J Radiat Oncol Biol Phys (1985) 0.88
Screening for early ovarian cancer. Radiology (1994) 0.88
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Cancer (2009) 0.88
Trisomy 12 in benign fibroma and granulosa cell tumor of the ovary. Gynecol Oncol (1990) 0.87
Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstet Gynecol (1985) 0.87
Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol (1993) 0.87
Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol (1990) 0.87
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. Br J Cancer (2011) 0.86
Percutaneous endoscopic gastrostomy for gastric decompression in metastatic gynecologic malignancies. Surg Gynecol Obstet (1993) 0.86
Measurement of estradiol-17-fatty acid esters in human tissues. J Clin Endocrinol Metab (1992) 0.86
Developmental regulation of angiotensin converting enzyme and angiotensin type 1 receptor in the rat pulmonary circulation. Am J Respir Cell Mol Biol (1996) 0.85
Sequelae of lateral ovarian transposition in unirradiated cervical cancer patients. Gynecol Oncol (1990) 0.85
Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol (1988) 0.85
Ultrastructural characteristics of endothelial permeability in chronic hypertension. Hypertension (1982) 0.84
Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. Int J Radiat Oncol Biol Phys (1998) 0.84
Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Gynecol Oncol (1996) 0.84
Prognostic value of clinical variables in invasive cervical cancer. Obstet Gynecol (1994) 0.84
Allelic deletion mapping of putative tumor suppressor genes on 17q in sporadic ovarian cancer. J Obstet Gynaecol (Tokyo 1995) (1995) 0.84
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer (2010) 0.84
Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol (2004) 0.83
Pleural and esophageal pressures in the upright body position. J Appl Physiol (1967) 0.83
Static tension is associated with increased smooth muscle cell DNA synthesis in rat pulmonary arteries. Am J Physiol (1995) 0.83
Type 2 herpes simplex virus and vulvar carcinoma in situ. N Engl J Med (1981) 0.83
Ovarian germ cell malignancies: the Yale University experience. Gynecol Oncol (1992) 0.82